Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG

Jordan U. Gutterman, Juan O. Cardenas, George R. Blumenschein, Gabriel Hortobagyi, Michael A. Burgess, Robert B. Livingston, Giora M. Mavligit, Emil J. Freireich, Jeffrey A. Gottlieb, Evan M. Hersh

Research output: Contribution to journalArticle

67 Scopus citations

Abstract

Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification. The results were compared with those in a comparable group of 44 patients treated with FAC alone immediately before the chemoimmunotherapy study. The remission rates (73% and 76% for FAC and FAC-BCG respectively) were similar in both studies. The durations of remission for patients on FAC-BCG (median 12 months) were longer than remissions achieved for patients given FAC alone (median 8 months) (P = 0.068). The most notable effect of BCG was on survival. Thus 21 out of 34 patients achieving remission on FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 11 out of 32 patients achieving remission on FAC (median 15 months) (P = 0.01). Twenty-six of the 45 patients given FAC-BCG were alive at the time of the last follow-up examination (median over 22 months) compared with 12 of the 44 patients given FAC (median 15 months) (P = 0.005). Although the apparent benefit of BCG could be explained by a maldistribution of some prognostic factors, the data suggest that further trials of chemoimmunotherapy of breast cancer should be carried out.

Original languageEnglish (US)
Pages (from-to)1222-1225
Number of pages4
JournalBritish Medical Journal
Volume2
Issue number6046
DOIs
StatePublished - Nov 1976

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG'. Together they form a unique fingerprint.

  • Cite this

    Gutterman, J. U., Cardenas, J. O., Blumenschein, G. R., Hortobagyi, G., Burgess, M. A., Livingston, R. B., Mavligit, G. M., Freireich, E. J., Gottlieb, J. A., & Hersh, E. M. (1976). Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG. British Medical Journal, 2(6046), 1222-1225. https://doi.org/10.1136/bmj.2.6046.1222